RxDoctor Payments Data

Brent Harkrider, MD

Interventional Pain Medicine · New Bern, NCNPI 1669826186

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,725 of the $14,422 with a category attached, or 74.4%. 43 manufacturers reported payments, led by Medtronic at 42.3% of the total. Reporting peaked in 2023 at $6,515 and has fallen 73.1% since, to $1,751 in 2025.

$14,422in general payments, 2019–2025

Across 487 payments — averaging $29.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Boston Scientific$2K
  • Si-bone, Inc.$830
  • Stimwave Technologies Incorporated$684
  • AbbVie$530
  • Collegium Pharmaceutical, Inc.$488
  • plus $3K from 37 others

What the payments were for

  • Consulting fees$1251%
  • Travel & lodging$3,57225%
  • Food & beverage$10,72574%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,422 in reported general payments places this provider in the 80th percentile of 45 interventional pain medicine providers in North Carolina.

See all interventional pain medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$200,131
Medicare patients
354
Services billed
3,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate38$17,956
Buprenorphine68$13,663
BelbucaBuprenorphine Hcl15$11,625
MovantikNaloxegol Oxalate17$7,095
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen194$6,603
Oxycodone Hcl298$5,742
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl59$4,559
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen151$3,712
Gabapentin215$2,953
Pregabalin121$2,908
Morphine Sulfate ErMorphine Sulfate79$1,869
Cyclobenzaprine Hcl117$1,753
Methadone Hcl55$1,525
Methocarbamol76$1,204
Lidocaine13$1,134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$488$29,58053 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 45 interventional pain medicine providers in North Carolina.

Other interventional pain medicine in New Bern

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →